Table of Content

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights


2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology


3. Executive Summary

3.1. Global Short Bowel Syndrome Market: Market Snapshot


4. Market Overview

4.1. Global Short Bowel Syndrome Market: Type Overview

4.2. Global Short Bowel Syndrome Market: Key Industry Developments

4.3. Market Dynamics

4.4. Drivers and Restraints Snapshot Analysis

4.5. Drivers

4.5.1. High cost of parenteral nutrition increases demand for SBS drugs

4.5.2. Favorable reimbursement scenario

4.6. Restraints

4.6.1. Side effects associated with SBS drugs

4.6.2. Non-availability of approved drugs globally

4.7. Opportunities

4.8. Global Short Bowel Syndrome Market Revenue Projections (US$ Mn), 2017–2027


5. Key Insights

5.1. Drivers & Restraints Impact Analysis

5.2. Value Chain Analysis

5.3. Short Bowel Syndrome: Disease Overview

5.4. Short Bowel Syndrome: Epidemiology

5.5. Rare Diseases Prevalence

5.6. Overview of Clinical Trials for Short Bowel Syndrome

5.7. Qualitative Analysis of GLP-2 Product

5.8. Research & Development Cost Analysis

5.9. Impact Analysis of Clinical Trials Cost on Orphan Drugs

5.10. Cost Analysis of Therapies using Orphan Drugs

5.11. Approved U.S. Orphan Indications, 1983–2015

5.12. Approved European Orphan Indications, 2019

5.13. Pricing Analysis

5.14. Orphan Drugs – Price Volume Analysis

5.15. Justifications for the High Cost of Gattex & Teduglutide

5.16. Regulations Scenario Assessment

5.17. Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia

5.18. Impact Analysis of Regulatory Scenario Assessment

5.19. Comparative Analysis of Orphan Drug Policies

5.20. Orphan Drug Manufacturing Companies – Acquisitions Timeline

5.21. Orphan Drugs Market- SWOT Analysis


6. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.1. Introduction

6.2. Global Short Bowel Syndrome Market Value and Forecast, by Drug Class

6.2.1. Glucagon-like Peptide-2 (GLP-2)

6.2.2. Growth Hormone

6.2.3. Glutamine

6.2.4. Others

6.3. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.4. Global Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class


7. Global Short Bowel Syndrome Market Analysis, by Region

7.1. Global Short Bowel Syndrome Market Value and Forecast, by Region, 2017–2027

7.1.1. North America

7.1.2. Europe

7.1.3. Japan

7.1.4. Rest of the World

7.2. Global Short Bowel Syndrome Market Analysis, by Region

7.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region


8. North America Short Bowel Syndrome Market Analysis

8.1. North America Short Bowel Syndrome Market

8.2. North America Short Bowel Syndrome Market Overview

8.3. North America Short Bowel Syndrome Market Value and Forecast, by Drug Class

8.3.1. Glucagon-like Peptide-2 (GLP-2)

8.3.2. Growth Hormone

8.3.3. Glutamine

8.3.4. Others

8.4. North America Short Bowel Syndrome Market Forecast, by Country

8.4.1. U.S.

8.4.2. Canada

8.5. North America Short Bowel Syndrome Market Attractiveness Analysis

8.5.1. By Drug Class

8.5.2. By Country


9. Europe Short Bowel Syndrome Market Analysis

9.1. Europe Short Bowel Syndrome Market

9.2. Europe Short Bowel Syndrome Market Overview

9.3. Europe Short Bowel Syndrome Market Value and Forecast, by Drug Class

9.3.1. Glucagon-like Peptide-2 (GLP-2)

9.3.2. Growth Hormone

9.3.3. Glutamine

9.3.4. Others

9.4. Europe Short Bowel Syndrome Market Forecast, by Country/Sub-region

9.4.1. U.K.

9.4.2. France

9.4.3. Germany

9.4.4. Spain

9.4.5. Italy

9.4.6. Rest of Europe

9.5. Europe Short Bowel Syndrome Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Country/Sub-region


10. Japan Short Bowel Syndrome Market Analysis

10.1. Japan Short Bowel Syndrome Market Key Findings

10.2. Japan Short Bowel Syndrome Market Overview

10.3. Japan Short Bowel Syndrome Market Value and Forecast, by Drug Class

10.3.1. Glucagon-like Peptide-2 (GLP-2)

10.3.2. Growth Hormone

10.3.3. Glutamine

10.3.4. Others

10.4. Japan Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class


11. Rest of the World Short Bowel Syndrome Market Analysis

11.1. Rest of the World Short Bowel Syndrome Market Key Findings

11.2. Rest of the World Short Bowel Syndrome Market Overview

11.3. Rest of the World Short Bowel Syndrome Market Value and Forecast, by Drug Class

11.3.1. Glucagon-like Peptide-2 (GLP-2)

11.3.2. Growth Hormone

11.3.3. Glutamine

11.3.4. Others

11.4. Rest of the World Short Bowel Syndrome Market Analysis, by Country/Sub-region

11.4.1. China

11.4.2. India

11.4.3. Australia/New Zealand

11.4.4. Middle East

11.4.5. Brazil


12. Competitive Landscape

12.1. Company Profiles

12.1.1. Shire plc (Takeda Pharmaceutical Company Limited)

12.1.1.1. Overview (HQ, Employee Strength, Business Segments)

12.1.1.2. Financials

12.1.1.3. Recent Developments

12.1.1.4. Strategy

12.1.2. Zealand Pharma A/S

12.1.2.1. Overview (HQ, Employee Strength, Business Segments)

12.1.2.2. Financials

12.1.2.3. Recent Developments

12.1.2.4. Strategy

12.1.3. Sancilio & Company, Inc.

12.1.3.1. Overview (HQ, Employee Strength, Business Segments)

12.1.3.2. Recent Developments

12.1.3.3. Strategy

12.1.4. OxThera

12.1.4.1. Overview (HQ, Employee Strength, Business Segments)

12.1.4.2. Recent Developments

12.1.4.3. Strategy

12.1.5. Nutrinia Ltd

12.1.5.1. Overview (HQ, Employee Strength, Business Segments)

12.1.5.2. Recent Developments

12.1.5.3. Strategy

12.1.6. Ardelyx, Inc.

12.1.6.1. Overview (HQ, Employee Strength, Business Segments)

12.1.6.2. Financials

12.1.6.3. Recent Developments

12.1.6.4. Strategy

12.1.7. Emmaus Life Sciences, Inc.

12.1.7.1. Overview (HQ, Employee Strength, Business Segments)

12.1.7.2. Financials

12.1.7.3. Recent Developments

12.1.7.4. Strategy

12.1.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)

12.1.8.1. Overview (HQ, Employee Strength, Business Segments)

12.1.8.2. Financials

12.1.8.3. Recent Developments

12.1.8.4. Strategy

12.1.9. Merck KGaA

12.1.9.1. Overview (HQ, Employee Strength, Business Segments)

12.1.9.2. Financials

12.1.9.3. Recent Developments

12.1.9.4. Strategy

12.1.10. Naia Pharmaceuticals, Inc.

12.1.10.1. Overview (HQ, Employee Strength, Business Segments)

12.1.10.2. Recent Developments

12.1.10.3. Strategy



List of Figures



Figure 1: Market Size Estimation Methodology

Figure 2: Market Snapshot Global Short Bowel Syndrome Market

Figure 3: Global Short Bowel Syndrome Market Revenue (US$ Mn) (2018)

Figure 4: Global Short Bowel Syndrome Market Top 3 Trends

Figure 5: Global Short Bowel Syndrome Market Key Drivers, Restraints, and Trends

Figure 6: Global Short Bowel Syndrome Market Value (US$ Mn) and Distribution by Geography, 2018 and 2027

Figure 7: Drivers and Restraints Snapshot Analysis (1/2)

Figure 8: Drivers and Restraints Snapshot Analysis (2/2)

Figure 9: Opportunity Analysis Global Short Bowel Syndrome Market

Figure 10: Global Short Bowel Syndrome Market Value (US$ Mn) and Forecast, 2017–2027

Figure 11: Porter’s Five Force Analysis Global Short Bowel Syndrome Market

Figure 12: Drivers Impact Analysis Short Bowel Syndrome (SBS) Market

Figure 13: Restraints Impact Analysis Short Bowel Syndrome (SBS) Market

Figure 14: Value Chain: Short Bowel Syndrome (SBS) Market (Gattex)

Figure 15: Pathophysiology Short Bowel Syndrome

Figure 16: Causes of SBS in Neonates in Neonatal Intensive Care Units (NICU)

Figure 17: Causes of SBS in Adults

Figure 18: Prevalence of Orphan (rare) Diseases

Figure 19: Amino Acid Sequence of Teduglutide (GLP-2)

Figure 20: Amino Acid Sequence of Natural GLP-2

Figure 21: Mode of Action of GLP-2 Product

Figure 22: Orphan Drugs Research & Development Cost (US$ Mn), 2014-2018

Figure 23: U.S. Average Cost of Therapies using Orphan Drugs per Patients (US$/Patients/Year)

Figure 24: Approved U.S. Orphan Indications, 1983–2015

Figure 25: Approved European Orphan Indications, 2019

Figure 26: Factors Contributing to Orphan Drugs Pricing Decision

Figure 27: Pricing of Certain Orphan Drugs (US$ per patient per year)

Figure 28: Factors for High Prices of Orphan Drugs

Figure 29: Orphan Drugs – Price Volume Analysis

Figure 30: Justifications for the High Cost of Gattex & Teduglutide

Figure 31: U.S. Regulatory Scenario Assessment Flow Chart

Figure 32: Regulatory Approval Process- Europe

Figure 33: Regulatory Approval Process- Japan

Figure 34: Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia (excluding financial viability and new dosage form medicines)

Figure 35: Impact Analysis of Regulatory Scenario Assessment

Figure 36: Orphan Drugs Market- SWOT Analysis

Figure 37: Introduction – Global Short Bowel Syndrome (SBS) Market, by Drug Class (2/2)

Figure 38: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 39: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glucagon-like Peptide-2 (GLP-2), 2017–2027

Figure 40: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Growth Hormone, 2017–2027

Figure 41: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glutamine, 2017–2027

Figure 42: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 43: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 44: Global Market Scenario

Figure 45: Introduction – Global Short Bowel Syndrome (SBS) Market: by Region (2/2)

Figure 46: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Region, 2018 and 2027

Figure 47: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Region

Figure 48: North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017–2027

Figure 49: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027

Figure 50: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country, 2019-2027

Figure 51: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 52: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country, 2018 and 2027

Figure 53: Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017–2027

Figure 54: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 55: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 56: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 57: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 58: Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017–2027

Figure 59: Japan Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class

Figure 60: Japan Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 61: Rest of the World (excluding Japan) Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017–2027

Figure 62: Global Short Bowel Syndrome (SBS) Market Share Analysis, by Company (2018)

Figure 63: Shire plc Internal Medicine Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017

Figure 64: Shire plc Breakdown of Net Sales (%), by Region/Country, 2017

Figure 65: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017

Figure 66: Shire plc SWOT ANALYSIS

Figure 67: Zealand Pharma A/S Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 68: Zealand Pharma A/S SWOT ANALYSIS

Figure 69: Sancilio & Company, Inc. SWOT ANALYSIS

Figure 70: OxThera SWOT ANALYSIS

Figure 71: Nutrinia Ltd. SWOT ANALYSIS

Figure 72: Ardelyx, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2018

Figure 73: Ardelyx, Inc. Breakdown of Net Sales, by Revenue Type, 2018

Figure 74: Ardelyx, Inc. Research & Development Cost 2015 -2017

Figure 75: Ardelyx, Inc. SWOT ANALYSIS

Figure 76: Emmaus Life Sciences, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2018

Figure 77: Emmaus Life Sciences, Inc. R&D Spending and Sales & Marketing Expenses (US$ Mn), Company Level, 2017–2018

Figure 78: Emmaus Life Sciences, Inc. Breakdown of Net Sales, by Service Type, 2018

Figure 79: Emmaus Life Sciences, Inc. SWOT ANALYSIS

Figure 80: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 81: Pfizer Inc. Breakdown of Net Sales, by Region/Country, 2018

Figure 82: Pfizer Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 83: Pfizer Inc. Breakdown of Net Sales, by Business Segment (%), 2018

Figure 84: SWOT ANALYSIS (Pfizer Inc.)

Figure 85: Merck KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 86: Merck KGaA R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017

Figure 87: Merck KGaA Breakdown of Net Sales (%), by Region, 2018

Figure 88: Merck KGaA Breakdown of Net Sales (%), by Business Segment, 2017

Figure 89: Merck KGaA SWOT ANALYSIS

Figure 90: Naia Pharmaceuticals, Inc. SWOT ANALYSIS

 

List of Tables



TABLE 1 Overview of Clinical Trials for Short Bowel Syndrome (1/2)

TABLE 2 Overview of Clinical Trials for Short Bowel Syndrome (2/2)

TABLE 3 Orphan Drugs Research & Development Cost (US$ Mn), 2014–2018

TABLE 4 Impact Analysis of Clinical Trials Cost on Orphan Drugs (1/2)

TABLE 5 Impact Analysis of Clinical Trials Cost on Orphan Drugs (2/2)

TABLE 6 Comparative Analysis of Orphan Drug Policies

TABLE 7 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 8 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Region, 2019–2027

TABLE 9 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 10 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country, 2017–2027

TABLE 11 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 12 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 13 Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027